Glassock RJ, Warnock DG, Delanaye P. The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat Rev Nephrol. 2017;13:104–14.
Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017;389:1238–52.
Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96:1048–50.
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–33.
Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392:2052–90.
Vanholder R, Annemans L, Bello AK, Bikbov B, Gallego D, Gansevoort RT, et al. Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. Clin Kidney J. 2021;14:1719–30.
Wanner C, Tonelli M. Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303–9.
Bidin MZ, Shah AM, Stanslas J, Seong CLT. Blood and urine biomarkers in chronic kidney disease: An update. Clin Chim Acta. 2019;495:239–50.
Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3:514–25.
Dhaun N, Bellamy CO, Cattran DC, Kluth DC. Utility of renal biopsy in the clinical management of renal disease. Kidney Int. 2014;85:1039–48.
Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80:806–21.
Beltrami C, Clayton A, Phillips AO, Fraser DJ, Bowen T. Analysis of urinary microRNAs in chronic kidney disease. Biochem Soc Trans. 2012;40:875–9.
Düsing P, Zietzer A, Goody PR, Hosen MR, Kurts C, Nickenig G, et al. Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. J Mol Med. 2021;99:335–48.
Legate KR, Montañez E, Kudlacek O, Fässler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol. 2006;7:20–31.
Hatem-Vaquero M, Griera M, García-Jerez A, Luengo A, Álvarez J, Rubio JA, et al. Peripheral insulin resistance in ILK-depleted mice by reduction of GLUT4 expression. J Endocrinol. 2017;234:115–28.
Ding L, Dong L, Chen X, Zhang L, Xu X, Ferro A, et al. Increased expression of integrin-linked kinase attenuates left ventricular remodeling and improves cardiac function after myocardial infarction. Circulation. 2009;120:764–73.
Hatem-Vaquero M, Griera M, Garcia-Ayuso D, Campillo S, Bohorquez L, Calleros L, et al. Integrin Linked Kinase (ILK) Downregulation as an Early Event During the Development of Metabolic Alterations in a Short-Term High Fat Diet Mice Model. Cell Physiol Biochem. 2020;54:71–87.
Hou J, Liu B, Zhu B, Wang D, Qiao Y, Luo E, et al. Role of integrin-linked kinase in the hypoxia-induced phenotypic transition of pulmonary artery smooth muscle cells: Implications for hypoxic pulmonary hypertension. Exp Cell Res. 2019;382:111476.
Du M, Wang Q, Li W, Ma X, Wu L, Guo F, et al. Overexpression of FOXO1 ameliorates the podocyte epithelial-mesenchymal transition induced by high glucose in vitro and in vivo. Biochem Biophys Res Commun. 2016;471:416–22.
Alique M, Civantos E, Sanchez-Lopez E, Lavoz C, Rayego-Mateos S, Rodrigues-Díez R, et al. Integrin-linked kinase plays a key role in the regulation of angiotensin II-induced renal inflammation. Clin Sci. 2014;127:19–31.
Dai HY, Zheng M, Lv LL, Tang RN, Ma KL, Liu D, et al. The roles of connective tissue growth factor and integrin-linked kinase in high glucose-induced phenotypic alterations of podocytes. J Cell Biochem. 2012;113:293–301.
de Frutos S, Luengo A, García-Jérez A, Hatem-Vaquero M, Griera M, O’Valle F, et al. Chronic kidney disease induced by an adenine rich diet upregulates integrin linked kinase (ILK) and its depletion prevents the disease progression. Biochim Biophys Acta Mol Basis Dis. 2019;1865:1284–97.
Serrano I, De Frutos S, Griera M, Medrano D, Rodríguez-Puyol M, Dedhar S, et al. Ilk conditional deletion in adult animals increases cyclic GMP-dependent vasorelaxation. Cardiovasc Res. 2013;99:535–44.
Herranz B, Marquez S, Guijarro B, Aracil E, Aicart-Ramos C, Rodriguez-Crespo I, et al. Integrin-linked kinase regulates vasomotor function by preventing endothelial nitric oxide synthase uncoupling: role in atherosclerosis. Circ Res. 2012;110:439–49.
Hortelano S, López-Fontal R, Través PG, Villa N, Grashoff C, Boscá L, et al. ILK mediates LPS-induced vascular adhesion receptor expression and subsequent leucocyte trans-endothelial migration. Cardiovasc Res. 2010;86:283–92.
Campillo S, Bohorquez L, Gutiérrez-Calabrés E, García-Ayuso D, Miguel V, Griera M, et al. Indoxyl sulfate- and P-cresol-induced monocyte adhesion and migration is mediated by integrin-linked kinase-dependent podosome formation. Exp Mol Med. 2022;54:226–38.
Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016;44:3865–77.
Zhang WR, Parikh CR. Biomarkers of Acute and Chronic Kidney Disease. Annu Rev Physiol. 2019;81:309–33.
Nikou S, Arbi M, Dimitrakopoulos FD, Sirinian C, Chadla P, Pappa I, et al. Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival. J Mol Histol. 2020;51:385–400.
Akrida I, Nikou S, Gyftopoulos K, Argentou M, Kounelis S, Zolota V, et al. Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype. Histol Histopathol. 2018;33:937–49.
Li M, Zhou H, Di J, Yang M, Jia F. ILK participates in renal interstitial fibrosis by altering the phenotype of renal tubular epithelial cells via TGF-β1/smad pathway. Eur Rev Med Pharmacol Sci. 2019;23:289–96.
Qi FH, Cai PP, Liu X, Si GM. Adenovirus-mediated P311 ameliorates renal fibrosis through inhibition of epithelial-mesenchymal transition via TGF-β1-Smad-ILK pathway in unilateral ureteral obstruction rats. Int J Mol Med. 2018;41:3015–23.
Raman A, Reif GA, Dai Y, Khanna A, Li X, Astleford L, et al. Integrin-Linked Kinase Signaling Promotes Cyst Growth and Fibrosis in Polycystic Kidney Disease. J Am Soc Nephrol. 2017;28:2708–19.
Liu BC, Tang TT, Lv LL, Lan HY. Renal Tubule Injury: a Driving Force toward Chronic Kidney Disease. Kidney Int. 2018;93:568–79.
Humphreys BD. Mechanisms of Renal Fibrosis. Annu Rev Physiol. 2018;80:309–26.
Akchurin OM, Kaskel F. Update on Inflammation in Chronic Kidney Disease. Blood Purif. 2015;39:84–92.
Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4:1551–8.
Hatem-Vaquero M, de Frutos S, Luengo A, González Abajo A, Griera M, Rodríguez-Puyol M, et al. Contribution of uraemic toxins to the vascular fibrosis associated with chronic kidney disease. Nefrologia. 2018;38:639–46.
Six I, Flissi N, Lenglet G, Louvet L, Kamel S, Gallet M, et al. Uremic Toxins and Vascular Dysfunction. Toxins. 2020;12:404.
Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr. 2012;22:149–56.
Tesch GH. Review: Serum and urine biomarkers of kidney disease: A pathophysiological perspective. Nephrology. 2010;15:609–16.
Nickolas TL, Forster CS, Sise ME, Barasch N, Solá-Del Valle D, Viltard M, et al. NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int. 2012;82:718–22.
Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Invest Suppl. 2008;241:78–83.
Lu X, Hu MC. Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease. Kidney Dis. 2017;3:15–23.
Trionfini P, Benigni A, Remuzzi G. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol. 2015;11:23–33.
Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020;16:269–88.
Petzuch B, Bénardeau A, Hofmeister L, Meyer J, Hartmann E, Pavkovic M, et al. Urinary miRNA Profiles in Chronic Kidney Injury-Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial Dysfunction. Toxicol Sci. 2022;187:35–50.
Cai W, Xu Y, Zuo W, Su Z. MicroR-542-3p can mediate ILK and further inhibit cell proliferation, migration and invasion in osteosarcoma cells. Aging. 2019;11:18–32.
Samieyan Dehkordi S, Mousavi SH, Ebrahimi M, Alizadeh SH, Hedayati Asl AA, Mohammad M, et al. Upregulation of hsa-miR-625-5p Inhibits Invasion of Acute Myeloid Leukemia Cancer Cells through ILK/AKT Pathway. Cell J. 2022;24:76–84.
Li J, Bao H, Zhang K, Yang X, Liu X, Li P, et al. MiR-542-3p drives renal fibrosis by targeting AGO1 in vivo and in vitro. Life Sci. 2020;255:117845.
Xu H, He Z, Zhang M, Zhou W, Xu C, He M, et al. RNA Seq and ceRNA Network Analysis of the Rat Model of Chronic Kidney Disease. Comb Chem High Throughput Screen. 2023;26:116–25.
Wang J, Duan L, Guo T, Gao Y, Tian L, Liu J, et al. Downregulation of miR-30c promotes renal fibrosis by target CTGF in diabetic nephropathy. J Diabetes Complications. 2016;30:406–14.
Vu TA, Lema I, Hani I, Cheval L, Atger-Lallier L, Souvannarath V, et al. miR-324-5p and miR-30c-2-3p Alter Renal Mineralocorticoid Receptor Signaling under Hypertonicity. Cells. 2022;11:1377.
Xiao Q, Tang Y, Luo H, Chen S, Chen R, Yan Z, et al. Sclerostin is involved in osteogenic transdifferentiation of vascular smooth muscle cells in chronic kidney disease-associated vascular calcification with non-canonical Wnt signaling. Ren Fail. 2022;44:1426–42.
Navarro-Quiroz E, Pacheco-Lugo L, Lorenzi H, Díaz-Olmos Y, Almendrales L, Rico E, et al. High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus. PLoS ONE. 2016;11:e0166202.
Yuan D, Zhao Y, Wang Y, Che J, Tan W, Jin Y, et al. Effect of integrin-linked kinase gene silencing on microRNA expression in ovarian cancer. Mol Med Rep. 2017;16:7267–76.
Add Comment